| 查看: 288 | 回复: 0 | |||
[交流]
HitGen and LEO Pharma Enter Research Collaboration
|
|
CHENGDU, China--(BUSINESS WIRE)--HitGen Ltd announced that the company has entered into a multi-target multi-year collaboration with LEO Pharma A/S , to discover novel small molecule leads for multiple therapeutic targets of interest to LEO Pharma. According to the agreement, HitGen will use its advanced technology platform, based on DNA-encoded library design, synthesis and screening to discover novel leads which will be licensed exclusively to LEO Pharma. Under the terms of the agreement, HitGen will receive an upfront payment and be eligible for milestone payments from LEO Pharma. Source: http://www.businesswire.com/news/home/20170807005326/en |
回复此楼» 猜你喜欢
细胞死亡新方式：铜死亡
已经有9人回复
-
安徽医科大学-药理学求博导
已经有1人回复
-
药物学论文润色/翻译怎么收费?
已经有154人回复
-
丙酮酸激酶的抑制剂和激动剂
已经有1人回复
-
脓毒症（盲肠结扎）
已经有22人回复
-
广西医科大学基础医学院自身免疫病课题组招收基础医学、药学和生物学等专业的研究生
已经有7人回复
-
[学习资料分享] FAERS数据库的不良反应挖掘(频数法/贝叶斯法)
已经有1人回复
-
招收医学、基础医学类调剂研究生
已经有0人回复
-
是否属于脾肾阳虚证
已经有0人回复
